Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity (NYSE:BSX)
· seekingalpha.com
Boston Scientific has suffered a 50% share price decline amid decelerating growth, but fundamentals-based valuation now appears attractive. Read more here.
The medical device sector offers a pretty stark rule of thumb—grow at 10% or more (often closer to 20% for smaller companies) and the valuation multiples will...